Posted by Michael Wonder on 23 Nov 2023
Cedazuridine with decitabine for patients with untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
23 November 2023 - NICE is unable to make a recommendation on the use of cedazuridine with decitabine (Inaqovi) for the first-line treatment of adults with acute myeloid leukaemia when intensive chemotherapy is unsuitable.
This is because Otsuka did not provide an evidence submission. NICE will review this decision if Otsuka decides to make a submission.
